GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biosergen AB (FRA:8N1) » Definitions » Total Receivables

Biosergen AB (FRA:8N1) Total Receivables : €0.38 Mil (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Biosergen AB Total Receivables?

Biosergen AB's Total Receivables for the quarter that ended in Sep. 2024 was €0.38 Mil.


Biosergen AB Total Receivables Historical Data

The historical data trend for Biosergen AB's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosergen AB Total Receivables Chart

Biosergen AB Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Total Receivables
0.40 0.73 0.37 0.44

Biosergen AB Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.43 0.44 2.11 0.62 0.38

Biosergen AB Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


Biosergen AB Total Receivables Related Terms

Thank you for viewing the detailed overview of Biosergen AB's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Biosergen AB Business Description

Traded in Other Exchanges
Address
Fogdevreten 2, Solna, SWE, 17165
Biosergen AB is a biotech company developing innovative antifungal drugs based on latest biopharmaceutical research and development from laboratory facilities in Trondheim, Norway, and several other places worldwide. The company is developing BSG005, a potentially disruptive antifungal drug, which has demonstrated significant safety and potency advantages over competing antifungals.

Biosergen AB Headlines

No Headlines